Steven J Budd1, M Elizabeth Hartnett. 1. Department of Ophthalmology, School of Medicine, University of North Carolina, 130 Mason Farm Rd, Campus Box 7040, Chapel Hill, NC 27599-7040, USA. hartnet@med.unc.edu
Abstract
OBJECTIVES: To determine expression of vascular endothelial growth factor (VEGF), pigment epithelium-derived factor, and their respective receptors in retinas using a model of retinopathy of prematurity. METHODS: Retinas isolated from a 50/10 oxygen (inspired oxygen cycled between 50% oxygen and 10% oxygen every 24 hours)-induced rat model of retinopathy of prematurity (50/10 OIR model), and from room air-raised rat pups (RA) at birth, age 14 days (persistent peripheral avascular retina in the 50/10 OIR model and complete retinal vascularization in RA) and age 18 days (intravitreous neovascularization in the 50/10 OIR model) were analyzed for messenger RNA of VEGF(164), neuropilin 1, neuropilin 2, VEGF receptor 1, VEGF receptor 2, pigment epithelium-derived factor, and pigment epithelium-derived factor receptor by real-time polymerase chain reaction. RESULTS: In the 50/10 OIR model compared with RA, fold changes in expression of VEGF(164), neuropilin 1, and neuropilin 2 were significantly increased at ages 14 and 18 days. A trend for increased fold change was noted in expression of VEGF receptor 2 at age 14 days and a significant increase at age 18 days in the 50/10 OIR model compared with RA. Pigment epithelium-derived factor receptor was significantly increased at age 14 days in the 50/10 OIR model compared with RA. CONCLUSION: Increased expression of VEGF(164) and angiogenic receptors were found in association with both avascular retina at day 14 and intravitreous neovascularization at day 18 in a relevant model of retinopathy of prematurity. CLINICAL RELEVANCE: Increased VEGF and angiogenic receptors may have a role in the development of peripheral avascular retina and stage 3 retinopathy of prematurity.
OBJECTIVES: To determine expression of vascular endothelial growth factor (VEGF), pigment epithelium-derived factor, and their respective receptors in retinas using a model of retinopathy of prematurity. METHODS: Retinas isolated from a 50/10 oxygen (inspired oxygen cycled between 50% oxygen and 10% oxygen every 24 hours)-induced rat model of retinopathy of prematurity (50/10 OIR model), and from room air-raised rat pups (RA) at birth, age 14 days (persistent peripheral avascular retina in the 50/10 OIR model and complete retinal vascularization in RA) and age 18 days (intravitreous neovascularization in the 50/10 OIR model) were analyzed for messenger RNA of VEGF(164), neuropilin 1, neuropilin 2, VEGF receptor 1, VEGF receptor 2, pigment epithelium-derived factor, and pigment epithelium-derived factor receptor by real-time polymerase chain reaction. RESULTS: In the 50/10 OIR model compared with RA, fold changes in expression of VEGF(164), neuropilin 1, and neuropilin 2 were significantly increased at ages 14 and 18 days. A trend for increased fold change was noted in expression of VEGF receptor 2 at age 14 days and a significant increase at age 18 days in the 50/10 OIR model compared with RA. Pigment epithelium-derived factor receptor was significantly increased at age 14 days in the 50/10 OIR model compared with RA. CONCLUSION: Increased expression of VEGF(164) and angiogenic receptors were found in association with both avascular retina at day 14 and intravitreous neovascularization at day 18 in a relevant model of retinopathy of prematurity. CLINICAL RELEVANCE: Increased VEGF and angiogenic receptors may have a role in the development of peripheral avascular retina and stage 3 retinopathy of prematurity.
Authors: B Oosthuyse; L Moons; E Storkebaum; H Beck; D Nuyens; K Brusselmans; J Van Dorpe; P Hellings; M Gorselink; S Heymans; G Theilmeier; M Dewerchin; V Laudenbach; P Vermylen; H Raat; T Acker; V Vleminckx; L Van Den Bosch; N Cashman; H Fujisawa; M R Drost; R Sciot; F Bruyninckx; D J Hicklin; C Ince; P Gressens; F Lupu; K H Plate; W Robberecht; J M Herbert; D Collen; P Carmeliet Journal: Nat Genet Date: 2001-06 Impact factor: 38.330
Authors: Robin E Bachelder; Elizabeth A Lipscomb; Xuena Lin; Melissa A Wendt; Neil H Chadborn; Britta J Eickholt; Arthur M Mercurio Journal: Cancer Res Date: 2003-09-01 Impact factor: 12.701
Authors: L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore Journal: Invest Ophthalmol Vis Sci Date: 1994-01 Impact factor: 4.799
Authors: Luz Consuelo Zepeda-Romero; Miguel Vazquez-Membrillo; Elva Adan-Castro; Francisco Gomez-Aguayo; Jose Alfonso Gutierrez-Padilla; Eusebio Angulo-Castellanos; Juan Carlos Barrera de Leon; Cesareo Gonzalez-Bernal; Manuel Alejandro Quezada-Chalita; Alonso Meza-Anguiano; Nundehui Diaz-Lezama; Gonzalo Martinez de la Escalera; Jakob Triebel; Carmen Clapp Journal: Pediatr Res Date: 2016-11-14 Impact factor: 3.756
Authors: Gunnel Hellgren; Chatarina Löfqvist; Anna-Lena Hård; Ingrid Hansen-Pupp; Magnus Gram; David Ley; Lois E Smith; Ann Hellström Journal: Pediatr Res Date: 2015-09-15 Impact factor: 3.756
Authors: Alyssa C Taylor; Thomas A Mendel; Katelyn E Mason; Katherine E Degen; Paul A Yates; Shayn M Peirce Journal: Invest Ophthalmol Vis Sci Date: 2012-08-13 Impact factor: 4.799
Authors: Haibo Wang; Zhihong Yang; Yanchao Jiang; John Flannery; Scott Hammond; Tal Kafri; Sai Karthik Vemuri; Bryan Jones; M Elizabeth Hartnett Journal: Invest Ophthalmol Vis Sci Date: 2014-02-04 Impact factor: 4.799
Authors: Yanchao Jiang; Haibo Wang; David Culp; Zhihong Yang; Lori Fotheringham; John Flannery; Scott Hammond; Tal Kafri; M Elizabeth Hartnett Journal: Invest Ophthalmol Vis Sci Date: 2014-02-10 Impact factor: 4.799